0IT Stock Chart & Stats
€7.75
€0.05(0.60%)
At close: 4:00 PM EDT
€7.75
€0.05(0.60%)
Day’s Range― - ―
52-Week Range€4.56 - €11.38
Previous CloseN/A
Volume0.00
Average Volume (3M)11.00
Market Cap
€148.02M
Enterprise Value€134.33M
Total Cash (Recent Filing)€61.74M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 25, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding21,216,438
10 Day Avg. Volume35
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.09Price Target Upside185.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of debt reduces refinancing and interest-burden risk while preserving financial flexibility. Meaningful equity provides a buffer for ongoing development spending and gives management more room to pursue its clinical program without the constraints typically associated with leveraged biotech operations.
Regenerative Medicine FocusA focused regenerative-medicine platform aimed at restoring muscle repair addresses a serious skeletal-muscle disorder and defines a clear development strategy. Initial concentration on Duchenne muscular dystrophy may help direct limited resources toward a specific clinical opportunity and build expertise around that indication.
Cash-flow Growth ModerationAlthough cash generation remains negative, the latest improvement in free-cash-flow growth indicates that the pace of deterioration has moderated. If maintained, better spending discipline could extend financial flexibility and support continued clinical development while the company works toward future revenue generation.
Bears Say
No Reported RevenueThe absence of revenue confirms that Satellos remains dependent on development financing rather than operating income. Without commercial sales, the company has limited internal funding capacity, and its ability to create durable value remains tied to successful clinical progress and eventual product commercialization.
Widening Net LossesLosses have expanded materially while revenue remains absent, indicating that spending is increasing faster than the business is producing operating income. Persistent widening losses can erode equity, reduce financial resilience, and require additional capital before the clinical programs can become self-funding.
Persistent Cash BurnNegative operating and free cash flow shows that reported losses translate into substantial cash outflows rather than being mainly non-cash expenses. Continued burn increases dependence on financing and can constrain the pace or breadth of clinical investment if funding conditions become less favorable.
Satellos Bioscience News
0IT FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was €4.56 and its highest was €11.38 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is €148.02M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Nov 25, 2026 which is in 46 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on Aug 13, 2026. The company reported -€0.486 earnings per share for the quarter, missing the consensus estimate of -€0.454 by -€0.033.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.53.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 21,216,438 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -€0.486 in its last earnings report, missing expectations of -€0.454. Following the earnings report the stock price went up 0.592%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in DE:0IT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Satellos Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.09 (185.02% Upside)
€22.09 (185.02% Upside)
Insider Transactions
Bought Shares
Worth €107.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.38%
12-Months-Change
Fundamentals
Return on Equity
-72.67%
Trailing 12-Months
Asset Growth
59.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
0IT Stock 12 Month Forecast
Average Price Target
€22.09
▲(185.02% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Helix BioPharma
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―